20 May Opinion: The 340B drug-pricing program, a critical MetroHealth patient lifeline, is under threat
“This spring, I find myself embracing the change of season and reflecting on the challenges of seasons past. For two years, we intensive-care professionals have cared for critically ill COVID-19 patients with ravaged lungs who clung for life on ventilators. We witnessed tragic and heartbreaking deaths. Patients who survived still endure a long road to full recovery. Through all the challenges, I was grateful our health system had the resources we needed to provide exceptional care to the critically ill.
But now, one crucial resource is under significant threat, and I worry what will happen during the next major public health emergency.”